SalvaRx Group plc Director/PDMR Dealing (4135G)

TIDMSALV

RNS Number : 4135G

SalvaRx Group plc

06 November 2018

6 November 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Director/PDMR Dealing

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that the Company has issued and allotted 172,460 ordinary shares of 2.5 pence each in the capital of the Company at a price of 23.2p per share ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the existing Ordinary Shares and were issued following the exercise of options by Jim Mellon and Dr Greg Bailey, non-executive Directors of the Company. The gross proceeds of the exercise amounting to GBP40,010.72 were set off against amounts owing by the Company to Messrs Mellon and Bailey.

The options were exercised pursuant to the Rule 9 Waiver detailed in the Company's AIM admission document dated 3 March 2016. Following the issue of the New Ordinary Shares, the interests of Messrs Mellon and Bailey in the issued share capital of the Company are as follows:

 
 Optionholder      Options exercised   Resultant interest    % of enlarged 
                                        in Ordinary Shares    share capital 
 
 Jim Mellon                   86,230            13,406,521            36.53 
 Dr Greg Bailey               86,230            13,406,521            36.53 
 

The interest of Jim Mellon in the above table includes interests held through Galloway Limited and Port Erin Biopharma Investments Limited.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 9 November 2018.

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued ordinary share capital will comprise 36,699,642 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. This figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

This announcement contains inside information.

Enquiries

 
 SalvaRx Group plc 
 Ian B. Walters, MD (Chief Executive)               Tel: [phone] 
 Northland Capital Partners Limited            Tel: [phone] 
  Nominated Adviser and Broker 
  Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
  Vadim Alexandre (Corporate Broking) 
 

The information below is set out in accordance with the requirements of the EU Market Abuse Regulation.

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                     James Mellon 
      ---------------------------------------  ---------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status                          Director 
      ---------------------------------------  ---------------------------------- 
 b)    Initial notification                     Initial 
        /Amendment 
      ---------------------------------------  ---------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                     SalvaRx Group plc 
      ---------------------------------------  ---------------------------------- 
 b)    LEI                                      213800G2OYVF7NTWRF98 
      ---------------------------------------  ---------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the                       Ordinary Shares of 2.5p each 
        financial instrument, 
        type of instrument 
 
       Identification code                      IM00BZ4SS228 
 
 b)    Nature of the transaction                Exercise of options 
      ---------------------------------------  ---------------------------------- 
 c)    Price(s) and volume(s) 
                                                --------------  --------------- 
                                                 Price(s)        Volume(s) 
                                                --------------  --------------- 
                                                 23.2p           86,230 
                                                --------------  --------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                      86,230 
 
  - Price                                  23.2p 
 
 e)    Date of the transaction                  31 October 2018 
      ---------------------------------------  ---------------------------------- 
 f)    Place of the transaction                 Outside a trading venue 
      ---------------------------------------  ---------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                     Gregory Bailey 
      ---------------------------------------  ---------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status                          Director 
      ---------------------------------------  ---------------------------------- 
 b)    Initial notification                     Initial 
        /Amendment 
      ---------------------------------------  ---------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                     SalvaRx Group plc 
      ---------------------------------------  ---------------------------------- 
 b)    LEI                                      213800G2OYVF7NTWRF98 
      ---------------------------------------  ---------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the                       Ordinary Shares of 2.5p each 
        financial instrument, 
        type of instrument 
 
       Identification code                      IM00BZ4SS228 
 
 b)    Nature of the transaction                Exercise of options 
      ---------------------------------------  ---------------------------------- 
 c)    Price(s) and volume(s) 
                                                --------------  --------------- 
                                                 Price(s)        Volume(s) 
                                                --------------  --------------- 
                                                 23.2p           86,230 
                                                --------------  --------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                      86,230 
 
  - Price                                  23.2p 
 
 e)    Date of the transaction                  31 October 2018 
      ---------------------------------------  ---------------------------------- 
 f)    Place of the transaction                 Outside a trading venue 
      ---------------------------------------  ---------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHUGGRAGUPRPUA

(END) Dow Jones Newswires

November 06, 2018 02:00 ET (07:00 GMT)